What Is Palvella Therapeutics, Inc. (PVLA) Worth in 2026?
According to the CirclFi Deep Alpha Valuation Engine, Palvella Therapeutics, Inc.'s intrinsic value is estimated at $71.88, suggesting the stock is overvalued at its current price of $151.97. With 7 out of 9 models flagging downside (-52.7% average return), the market may be pricing in unsustainable growth. Notably, Sentiment SOTP sees the most upside at +24.5% (fair value: $189.20), while ML-RIV is the most conservative at -96.7% ($5.09). The spread between these extremes — +121.1% — reveals how different analytical frameworks can reach starkly different conclusions.
What Do the Models Say About PVLA?
9 of 13 models are currently active for PVLA. Of these, 1 model suggests upside while 8 models suggest overvaluation. The Bayesian DCF estimates PVLA's intrinsic value at $51.84, implying -65.9% downside from the current price. See which stocks rank higher →
How Does PVLA Rank in Pharmaceutical Preparations?
Among 431 Pharmaceutical Preparations stocks, PVLA ranks #259 by Quality of Company score. CirclFi's QOC score of 4.6/10 evaluates 32 fundamental signals. A score of 4.6 reflects mixed fundamentals.
See all Most Undervalued Pharmaceutical Preparations Stocks →
As a healthcare company, Palvella Therapeutics, Inc. operates in a sector where clinical trial success rate is a critical driver of valuation. Investors evaluating PVLA should weigh these sector-specific dynamics alongside our model-derived fair values.
Is PVLA a Value Trap?
CirclFi's Value Trap algorithm assigns PVLA a score of 24/100 (SAFE). This indicates minimal risk. Fundamentals are healthy. The score cross-references apparent undervaluation against fundamental deterioration signals. Browse lowest value-trap stocks →
Multi-Model Methodology
9 of 13 models are active for Palvella Therapeutics, Inc.. Moderate coverage provides meaningful perspective. Each model applies a fundamentally different valuation philosophy. See the complete methodology →
According to the CirclFi 32-factor quality framework, Palvella Therapeutics, Inc.'s fundamental quality profile registers 4.6/10. This mixed score captures the company's profitability depth, growth consistency, balance sheet resilience, and shareholder return track record.
The gap between the most bullish and bearish model spans +121.1% — demonstrating why single-model analysis is dangerous. Browse all stocks with 13-model coverage →
Data Sources & Confidence
Every PVLA valuation is built from SEC EDGAR XBRL filings — 700+ standardized financial tags. Macroeconomic context from FRED calibrates discount rates, while GDELT news sentiment feeds into our Sentiment SOTP model. All pipelines run daily. Read the complete data methodology →
Across PVLA's 9 active models, average confidence is 21%. Lower confidence may reflect limited history or high volatility.
CirclFi's output is a research starting point, not a buy/sell signal. All data updates daily. Read the full methodology →
Buy with Gumroad